Manifestation of subacute cutaneous lupus erythematosus during treatment with anti-PD-1 antibody cemiplimab – a case report
Simon Fietz, Anne Fröhlich, Cornelia Mauch, Luka de Vos-Hillebrand, Tanja Fetter, Jennifer Landsberg, Friederike Hoffmann, Judith Sirokay · 2023
Read Manifestation of subacute cutaneous lupus erythematosus during treatment with anti-PD-1 antibody cemiplimab – a case report by Simon Fietz, Anne Fröhlich, Cornelia Mauch, Luka de Vos-Hillebrand, Tanja Fetter, Jennifer Landsberg, Friederike Hoffmann, Judith Sirokay (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10748382.txt.
Description
Simon Fietz and seven co-authors report a 2023 case of a skin ill sparked by a cancer drug. The drug frees the immune system to fight a grave skin cancer, and it often works well. Yet freed immunity can turn on the body, and skin side effects are among the most common harms.
Their patient grew a lupus-like rash on sun-lit skin while on the drug, with lab marks to match. Lupus under this drug class is rare, and no case had been logged under this drug itself. The report urges care teams to watch for this rash and treat it early.
Catalog record
| CREATOR | Simon Fietz, Anne Fröhlich, Cornelia Mauch, Luka de Vos-Hillebrand, Tanja Fetter, Jennifer Landsberg, Friederike Hoffmann, Judith Sirokay |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 12 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |